Case Report

Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure

Urvi A. Shah, Sengottuvel Viswanathan, Beamon Agarwal, Aditi Shastri, Ioannis Mantzaris, Murali Janakiram, Noah Kornblum, Ira Braunschweig, Amit Verma, Yang Shi, John Reinus, and Olga Derman

1Department of Oncology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA
2Department of Pathology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA
3Department of Medicine, Division of Hepatology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA

Correspondence should be addressed to Urvi A. Shah; shahu@mskcc.org

Received 27 June 2018; Accepted 15 October 2018; Published 3 December 2018

Copyright © 2018 Urvi A. Shah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

SOS is a rare complication of stem cell transplantation and has significant morbidity and mortality. We present three cases of SOS and highlight underlying risk factors for its development, such as impaired clearance of alkylating agents (especially melphalan) in patients with renal failure and prolonged infection. Although, melphalan and cyclophosphamide cause SOS less commonly than alkylating agents such as busulfan, physicians must use caution when administering these drugs to patients with underlying comorbidities such as renal failure that may increase the likelihood of development of SOS. This is due to unpredictable pharmacokinetics in patients with renal failure and therefore close drug monitoring is required. With the recent FDA approval of defibrotide in 2016, outcomes of SOS have improved and physician awareness is important for prompt diagnosis and treatment.

1. Introduction

Sinusoidal obstruction syndrome (SOS), previously known as venoocclusive disease (VOD), is a rare life-threatening condition seen most commonly after hematopoietic stem cell transplantation (HSCT). Patients with SOS were managed with supportive care until 2016, when defibrotide was FDA approved for treatment of this disorder. We present three cases of SOS and highlight underlying risk factors for its development, such as impaired clearance of alkylating agents in patients with renal failure and prolonged infection.

2. Case Presentation

2.1. Case 1

A 52-year-old woman with kappa light chain multiple myeloma who was noncompliant with treatment presented one month after diagnosis with plasma cell leukemia and end-stage renal disease (ESRD) requiring hemodialysis (HD). She was treated with one cycle of bortezomib, doxorubicin, and dexamethasone and then, due to noncompliance, switched to four cycles of bortezomib, cyclophosphamide, and dexamethasone (CyBorD). She was mobilized with filgrastim followed by an autologous HSCT and melphalan (140 mg/m²) therapy. After transplantation, she developed Enterobacter and MRSA bacteremia that was treated with colistin and vancomycin for 14 days. Her total serum bilirubin level began to rise on treatment day seven and peaked at 7.8 mg/dl on treatment day 15. She also developed hepatomegaly, ascites, and had a ≥10% weight gain. Liver biopsy on treatment day 14 showed SOS (Figure 1). She was treated with ursodiol and subsequently recovered.

2.2. Case 2

A 53-year-old man with kappa light chain multiple myeloma and ESRD on HD was treated with five cycles of CyBorD followed by high-dose cyclophosphamide mobilization and autologous HSCT with melphalan 140 mg/m² therapy. His subsequent course was complicated by neutropenic fever with Streptococcus sanguinis...
bacteremia treated with vancomycin, cefazolin, and metronidazole. He had no history of liver disease, but his total serum bilirubin level was 3.4 mg/dl at the time of transplantation and peaked on treatment day 24 at 22 mg/dl. Imaging revealed ascites. Liver biopsy on treatment day 16 was consistent with SOS (Figure 1). He was treated with ursodiol and died on treatment day 25 before he could receive defibrotide under compassionate use.

2.3. Case 3. A 57-year-old man with kappa light chain multiple myeloma was treated for approximately two years with CyBorD. The patient had ESRD and required HD. CyBorD treatment was stopped when he was diagnosed with Staphylococcus epidermidis endocarditis that was treated with vancomycin followed by ampicillin-sulbactam for one month. His myeloma subsequently relapsed and stem cells were collected with filgrastim and plerixafor mobilization. Five days after collection, he presented with jaundice and a total bilirubin level of 12 mg/dl which peaked at 15.9 mg/dl one month later. Liver histology showed SOS without myeloma (Figure 1). The patient was treated with ursodiol. He was then lost to follow-up and HSCT was not performed.

These three patients with multiple myeloma and ESRD were treated with alkylating agents and autologous HSCT; each had prolonged infection and developed severe SOS in case 1, very severe SOS in case 2, and moderate SOS in case 3 based on proposed grading of SOS severity by EBMT criteria [1] (Table 1). Although case 3 did not have a HSCT, he was exposed to prolonged periods of alkylating agents and antibiotics such as vancomycin in the setting of a serious infection and renal dysfunction which are all underlying risk factors (Table 2). Patients with renal failure are at a greater than normal risk of developing drug-induced SOS because of altered pharmacokinetics, with marked interindividual variation [2].

3. Discussion

SOS is a rare disease with significant morbidity and mortality. In the pretransplantation era, it was rarely seen and
usually occurred in association with bush-tea consumption, high-dose chemotherapy, or treatment with other drugs. [3] The first fatal posttransplantation case of SOS was reported in 1979 in a patient with refractory acute leukemia [4]. In 135 reports of patients with autologous or allogeneic HSCTs, in 1979 in a patient with refractory acute leukemia [4]. In the majority of cases. Moderate to severe SOS is associated with painful hepatomegaly, rapid weight gain, ascites, and jaundice. If SOS progresses to multiorgan failure, mortality is as high as 84% [5]. Mortality from SOS has declined since the introduction of debridement in 1997, the only significant change in treatment for these patients in the last 20 years [8]. Recently in March 2016, the U.S. FDA approved debridemtion of melphalan, a polydextrose isomalt, which can treat hepatic VOD in patients with kidney or lung abnormalities after a HSCT and a delay in administration is associated with worse outcomes. The approval was based on survival at treatment day 100 after HSCT in two prospective clinical trials (phase II [9] and III [10]) as well as an expanded access study [11]. The treatment day 100 survival rates in these studies were 44% [9], 38% [10], and 45% [11], respectively, as compared to older published reports and analyses of patient level data prior to debridement availability where it is significantly lower at 21–31% [12].

Multiple risk factors predispose patients to develop SOS [13]. Most commonly implicated are the conditioning regimen and the type of HSCT. Underlying liver dysfunctions, such as abnormal liver enzyme levels and hepatitis B or C infections, are independent risk factors for the development of SOS after HSCT [14]. Treatment with antimicrobials, such as vancomycin, amphotericin, and acyclovir, also is associated with SOS [14, 15]; their use is considered an indirect marker for persistent fever and infection [14].

There is a lower mean incidence of SOS after autologous HSCT than after allogeneic HSCT (8.7% vs 12.9%) [5]. Conditioning regimens determine the overall risk of developing SOS; several alkylating agents given in high doses have been associated with development of SOS in this setting [3, 16]. Alkylating-agent metabolites have been shown in vitro to deplete hepatic glutathione levels, inducing oxidative stress [17]. SOS is believed to be caused by cytoreductive injury to hepatocytes and endothelial cells in zone three of the liver acinus. This is strongly influenced by factors that induce the release of tumor necrosis factor-α (TNF-α) leading to coagulation with obstruction of hepatic sinusoids and venules [15] (Figure 2).

The most commonly implicated alkylating agent for the development of SOS is busulfan. Unpredictable absorption and hepatic first-pass metabolism of oral busulfan led to the development of IV busulfan, which is associated with a significantly lower incidence of SOS [18]. Use of Bayesian individualization of busulfan dosage also may lower the SOS rate [19].

Cyclophosphamide, another alkylator, may cause elevation of serum bilirubin levels, SOS, and mortality in direct proportion to drug exposure [20]. The International Myeloma Working Group does not recommend cyclophosphamide dose reduction in myeloma patients with renal impairment, given that it is relatively safe [21]. Although cyclophosphamide dose adjustment is not necessary in patients with moderate renal impairment, this drug must be used with caution in persons with severe renal impairment because studies have shown that renal impairment causes decreased excretion of cyclophosphamide and its metabolites, increasing the risk of toxicity [22–25].

Standard-dose melphalan is rarely associated with hepatotoxicity [26]. Melphalan is metabolized by hydrolysis and dechlorination by hepatic cytochrome P450. At high doses, melphalan causes transient elevations of liver enzyme levels [27]. Preclinical studies show that melphalan induces caspase-dependent apoptosis of hepatocytes by increasing membrane-bound TNF in Kupffer cells [28]. Direct cytotoxic injury causing sinusoidal endothelial cell death and extrusion into sinusoids, with subsequent sinusoidal and hepatic venular obstruction is another potential mechanism (https://livertox.nih.gov/Melphalan.htm) (Figure 2).

### Table 2: Well-known risk factors for SOS (adapted from [1, 3]).

| Transplant-related factors                      | Unrelated donor | HLA-mismatched donor | Non-T-cell-depleted transplant | Myeloablative-conditioning regimen | Oral or high-dose busulfan-based regimen | High-dose total body irradiation-based regimen | Second HSCT | GVHD prophylaxis regimen |
|------------------------------------------------|-----------------|----------------------|-------------------------------|-----------------------------------|-----------------------------------------|-----------------------------------------------|-------------|------------------------|
| Patient and disease-related factors            | Old age         | Karnofsky score below 90% | Metabolic syndrome            | Female receiving norethisterone   | Advanced disease (beyond second CR or relapse/refractory) | Thalassemia                                   | Genetic factors (GSTM1 polymorphism, C282Y allele, MTHFR 677CC/1298CC haplotype) | Infection/antibiotic/antiviral use (vancomycin, acyclovir) | Renal dysfunction due to impaired drug clearance |

Hepatic related

- Elevated liver function tests
- Cirrhosis
- Active viral hepatitis
- Abdominal or hepatic irradiation
- Previous use of gemtuzumab ozogamicin or inotuzumab ozogamicin
- Hepatotoxic drugs
- Iron overload


Although melphalan is eliminated from plasma primarily by chemical hydrolysis to noncytotoxic monohydroxy and dihydroxy metabolites [29], it is both secreted and reabsorbed by the renal tubules. Therefore, its clearance is renalfunction-dependent [2]. For high-dose melphalan (200 mg/m²), a reduced dose of 140 mg/m² is used when the creatinine clearance is less than 60 ml/min [30]. Pharmacokinetic studies have demonstrated large interindividual variations (10-fold) in melphalan excretion [27, 31–33]. Some early studies recommended dosing based on the pharmacokinetic response to a test dose to minimize toxicity [34]. Given the interindividual variability in elimination, optimal melphalan dosing in patients with a creatinine clearance less than 60 ml/min is difficult [2], possibly exposing these patients to a greater risk of hepatotoxicity and hematologic toxicity [35]. Melphalan is not cleared to any significant degree by hemodialysis; therefore dose adjustment is dependent on renal function and not dialysis status.

High-dose melphalan treatment in preparation for HSCT, however, has rarely been associated with SOS. A study that assessed the safety of autologous HSCT in six patients with multiple myeloma and chronic renal failure noted that one patient who was treated with busulfan and melphalan at 80 mg/m² as a preconditioning regimen developed SOS on treatment day 15 [33]. Cases of severe SOS in patients with normal renal function have been reported after pre-conditioning treatment with melphalan 200 mg/m² in one patient who received an autologous HSCT [36] and in two patients after tandem HSCTs [37, 38].

In 2007 the Spanish Myeloma Group studied patients with newly diagnosed multiple myeloma treated with a total of six cycles of alternating VBMCP/VBAD chemotherapy followed by oral busulfan and melphalan 140 mg/m² and autologous HSCT. During two years of follow-up, a number of clinical episodes resembling SOS were seen. Consequently, the protocol was modified, and patients were treated with melphalan 200 mg/m² only. Three years later, after a total of 734 patients had undergone a first autologous HSCT, the authors noted an 8% incidence of SOS (2% mortality) in patients treated with busulfan and melphalan as compared to a 0.4% incidence (0.2% mortality) in the patients treated with melphalan alone. This trial showed that melphalan alone can cause SOS but this complication is much more common when melphalan is used in combination with busulfan [39].

4. Conclusion

Although melphalan and cyclophosphamide cause SOS less commonly than alkylating agents such as busulfan, physicians must use caution when administering these drugs to patients with underlying renal failure, liver disease, or prolonged infection and when they are given along with alkylating drugs. Close monitoring of patients with underlying risk factors for the development of SOS and prompt treatment with defibrotide if SOS is suspected can decrease the morbidity and mortality associated with this diagnosis.

Conflicts of Interest

There are no conflicts of interest to disclose.

References

[1] M. Mohty, F. Malard, M. Abecassis et al., “Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation,” Bone Marrow Transplantation, vol. 51, no. 7, pp. 906–912, 2016.

[2] F. Esma, M. Salvini, R. Troia, M. Boccadoro, A. Larocca, and C. Pautasso, “Melphalan hydrochloride for the treatment of multiple myeloma,” Expert Opinion on Pharmacotherapy, vol. 18, no. 11, pp. 1127–1136, 2017.

[3] J. H. Dalle and S. A. Giralt, “Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment,” Biology of blood and marrow transplantation: journal of the American Society
for Blood and Marrow Transplantation, vol. 22, no. 3, pp. 400–409, 2016.

[4] P. Jacobs, J. L. Miller, C. J. Uys, and B. E. Dietrich, “Fatal veno-occlusive disease of the liver after chemotherapy, whole-body irradiation and bone marrow transplantation for refractory acute leukaemia,” South African medical journal, vol. 55, no. 1, pp. 5–10, 1979.

[5] J. A. Coppell, P. G. Richardson, R. Soiffer et al., “Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome,” Biology of Blood and Marrow Transplantation, vol. 16, no. 2, pp. 157–168, 2010.

[6] G. B. McDonald, P. Sharma, D. E. Matthews, H. M. Shulman, and E. Donnall Thomas, “Venoocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors,” Hepatology, vol. 4, no. 1, pp. 116–122, 1984.

[7] R. J. Jones, K. S. K. Lee, W. E. Beschornor et al., “Venoocclusive disease of the liver following bone marrow transplantation,” Transplantation, vol. 44, no. 6, pp. 778–783, 1987.

[8] E. Carreras, M. Díaz-Beyá, L. Rosiñol, C. Martínez, F. Fernández-Avilés, and M. Rovira, “The incidence of venoocclusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade,” Biology of Blood and Marrow Transplantation, vol. 17, no. 11, pp. 1713–1720, 2011.

[9] P. G. Richardson, R. J. Soiffer, J. H. Antin et al., “Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial,” Biology of Blood and Marrow Transplantation, vol. 16, no. 7, pp. 1005–1017, 2010.

[10] P. G. Richardson, M. L. Riches, N. A. Kerman et al., “Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure,” Blood, vol. 127, no. 13, pp. 1656–1665, 2016.

[11] P. G. Richardson, A. R. Smith, B. M. Triplett et al., “Defibrotide for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome: interim results from a treatment IND study,” Biology of Blood and Marrow Transplantation, vol. 23, no. 6, pp. 997–1004, 2017.

[12] P. G. Richardson, A. R. Smith, B. M. Triplett et al., “Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves day +100 survival following hematopoietic stem cell transplantation,” British Journal of Haematology, vol. 178, no. 1, pp. 112–118, 2017.

[13] M. Mohty, F. Malard, M. Abecassis et al., “Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT),” Bone Marrow Transplantation, vol. 50, no. 6, pp. 781–789, 2015.

[14] G. B. McDonald, M. S. Hinds, L. D. Fisher et al., “Venoocclusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients,” Annals of Internal Medicine, vol. 118, no. 4, pp. 255–267, 1993.

[15] H. M. Shulman and W. Hinterberger, “Hepatic veno-occlusive disease—liver toxicity syndrome after bone marrow transplantation,” Bone Marrow Transplantation, vol. 10, no. 3, pp. 197–214, 1992.

[16] P. D. Tsirigotis, I. B. Resnick, B. Avni et al., “Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen,” Bone Marrow Transplantation, vol. 49, no. 11, pp. 1389–1392, 2014.

[17] L. D. DeLeve and X. Wang, “Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes,” Pharmacology, vol. 60, no. 3, pp. 143–154, 2000.

[18] A. Kashyap, J. Wingard, P. Cagnoni et al., “Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality,” Biology of Blood and Marrow Transplantation, vol. 8, no. 9, pp. 493–500, 2002.

[19] K. Brice, B. Valerie, G. Claire et al., “Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics,” Pharmacoepidemiology and Drug Safety, vol. 17, no. 2, pp. 135–143, 2008.

[20] G. B. McDonald, J. T. Slattery, M. E. Bouvier et al., “Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation,” Blood, vol. 101, no. 5, pp. 2043–2048, 2003.

[21] M. A. Dimopoulos, P. Sonneveld, N. Leung et al., “International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment,” Journal of Clinical Oncology, vol. 34, no. 13, pp. 1544–1557, 2016.

[22] C. Ekhart, J. M. Kerst, S. Rodenhuis, J. H. Beijnen, and A. D. R. Huijtema, “Altered cyclophosphamide and thiopeta pharmacokinetics in a patient with moderate renal insufficiency,” Cancer Chemotherapy and Pharmacology, vol. 63, no. 2, pp. 375–379, 2009.

[23] F. D. Juma, H. J. Rogers, and J. R. Trounce, “Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites,” European Journal of Clinical Pharmacology, vol. 19, no. 6, pp. 443–451, 1981.

[24] H. T. Mouridsen and E. Jacobsen, “Pharmacokinetics of cyclophosphamide in renal failure,” Acta Pharmacologica et Toxicologica, vol. 36, Suppl 5, pp. 409–414, 1975.

[25] V. Bramwell, R. T. Calvert, G. Edwards, H. Scariffe, and D. Crowther, “The disposition of cyclophosphamide in a group of myeloma patients,” Cancer Chemotherapy and Pharmacology, vol. 3, no. 4, pp. 253–259, 1979.

[26] P. D. King and M. C. Perry, “Hepatotoxicity of chemotherapy,” The Oncologist, vol. 6, no. 2, pp. 162–176, 2001.

[27] J. L. Lee, T. Gooley, W. Bensinger, K. Schiffner, and G. B. McDonald, “Veno-occlusive disease of the liver after busulfan, melphalan, and thiopeta conditioning therapy: incidence, risk factors, and outcome,” Biology of Blood and Marrow Transplantation, vol. 5, no. 5, pp. 306–315, 1999.

[28] M. Kresse, M. Latta, G. Kunstle et al., “Kupffer cell-expressed membrane-bound TNF mediates melphalan hepatotoxicity via activation of both TNF receptors,” Journal of Immunology, vol. 175, no. 6, pp. 4076–4083, 2005.

[29] D. S. Alberts, S. Y. Chang, H. S. G. Chen et al., “Kinetics of intravenous melphalan,” Clinical Pharmacology and Therapeutics, vol. 26, no. 1, pp. 73–80, 1979.

[30] M. A. Dimopoulos, E. Terpos, A. Chanan-Khan et al., “Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group,” Journal of Clinical Oncology, vol. 28, no. 33, pp. 4976–4984, 2010.
[31] G. Tricot, D. S. Alberts, C. Johnson et al., “Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study,” Clinical cancer research, vol. 2, no. 6, pp. 947–952, 1996.

[32] P. E. Kintzel and R. T. Dorr, “Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function,” Cancer Treatment Reviews, vol. 21, no. 1, pp. 33–64, 1995.

[33] P. Tosi, E. Zamagni, S. Ronconi et al., “Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure,” Leukemia, vol. 14, no. 7, pp. 1310–1313, 2000.

[34] B. Tranchand, Y. D. Ploin, M. P. Minuit et al., “High-dose melphalan dosage adjustment: possibility of using a test-dose,” Cancer Chemotherapy and Pharmacology, vol. 23, no. 2, pp. 95–100, 1989.

[35] K. Carlson, M. Hjorth, L. M. Knudsen, and The Nordic Myeloma Study Group, “Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure—a retrospective analysis and recommendations for dose adjustment,” British Journal of Haematology, vol. 128, no. 5, pp. 631–5, 2005.

[36] T. K. Dolai, K. S. Nataraj, M. Bhattacharya, and M. K. Ghosh, “Veno-occlusive disease following high dose melphalan,” Indian journal of hematology & blood transfusion, vol. 28, no. 1, pp. 62–63, 2012.

[37] S. I. Labidi, C. Sebban, H. Ghesquières, E. V. Nicolas, and P. Biron, “Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan,” International Journal of Hematology, vol. 88, no. 3, pp. 291–3, 2008.

[38] J. L. Harousseau, N. Milpied, J. P. Laporte et al., “Double-intensive therapy in high-risk multiple myeloma,” Blood, vol. 79, no. 11, pp. 2827–2833, 1992.

[39] E. Carreras, L. Rosiñol, M. J. Terol et al., “Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients,” Biology of blood and marrow transplantation, vol. 13, no. 12, pp. 1448–1454, 2007.